Anti-parasite lipids, compositions and methods

Specific lipids disintegrate parasite eggs and oocysts on body surfaces, addressing the ineffectiveness of traditional treatments by effectively killing these resistant organisms.

WO2026239423A1PCT designated stage Publication Date: 2026-11-19CAPRETTO EHF
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IS2026/050003
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-18
Publication Date
2026-11-19

Smart Images

  • Figure IMGF000011_0001
    Figure IMGF000011_0001
  • Figure IMGF000012_0001
    Figure IMGF000012_0001
Patent Text Reader

Abstract

This invention relates to novel methods to disintegrate eggs and / or oocyte of parasites, known to be much more resistant to chemical disinfection than bacteria, using anti- parasitic lipids comprising short and middle chain length monoglycerides optionally administered together with C8-C12 fatty acid, in particular to disintegrate eggs and / or oocysts infections in the nasal, ocular, otal, pharynx, larynx, sinuses, oral cavity, vaginal or dermal / skin surface of a mammal.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Anti-parasite lipids, compositions and methods

[0002] FIELD

[0003] This invention relates to novel formulations with the ability to kill eggs and / or oocysts released from parasites and therapeutic and preventive medical methods and use.

[0004] BACKGROUND

[0005] Killing or inactivating schistosomiasis eggs (and similar parasite eggs) according to the state of the art involves a combination of sanitation, chemical treatment, heat, and sometimes UV radiation. The best method depends on the context, whether it's in water, soil, or on contaminated materials. The methods used in the art are: (a) Chemical disinfection such as using chlorine in water. Schistosome eggs are much more resistant than bacteria, so higher doses and contact time are needed than when disinfection is applied to eliminate bacteria. The limitations are that chlorine is not always fully effective against eggs unless concentrations are very high. Other chemicals that have been used include lime (calcium hydroxide) or raising pH to above >12, which kills most parasite eggs within 24-48 hours; (b) Heat treatment using boiling or hot water (>70°C) is effective at killing schistosomiasis eggs within minutes, or having sustained temperatures >50°C for several days will kill helminth eggs; (c) UV radiation in water systems can damage DNA in eggs, reducing infectivity, though it is less effective than for bacteria or viruses. This method requires high doses and well-designed systems to be reliable. These methods, however, are not applicable when there is a need to treat helminth eggs or parasite eggs such as schistosomiasis eggs, that are attached to a body surface such as the vagina, Gl tract, skin or other surfaces such as cloths, furniture, floors and surfaces people touch or are in contact with.

[0006] There are several published reports on antiviral and antibacterial activities of milk lipids (J. K. Welsh et al. Use of Semliki Forest virus to identify lipid-mediated antiviral activity and anti-alphavirus immunoglobulin A in human milk, Infect. Immun. 19, 395-401, 1978; J. K. Welsh et al. Effect of antiviral lipids, heat and freezing on the activity of viruses in human milk, J. Infect. Dis. 140,322-328,1979; J. J. Kabara, Fatty acids and derivatives as antimicrobial agents. In: The pharmacological effect of lipids. Edited by J. J. Kabara. The American Oil Chemists Society, St.Louis, Mo., 1978, pp. 1-13; C. E. Isaacs, H. Thormar et al., Membrane disruptive effect of human milk: Inactivation of enveloped viruses, J. Infect. Dis. 154, 966-971, 1986; C. E. Isaacs and H. Thormar,P16103PC00

[0007] Human milk lipids inactivate enveloped viruses. In: Breast feeding, Nutrition, Infection and Infant Growth in Developed and Emerging Countries. Edited by S. A. Atkinson, L. A. Hanson, R. K. Chandra. ARTS Biomedical Publ. St. Johns, Newfoundland, Canada.

[0008] 1990, pp. 161-174; C. E. Isaacs et al., Antiviral and antibacterial lipids in human milk and infant formula feeds, Arch. Dis. Childhood 65, 861-864, 1990; C. E. Isaacs and H. Thormar, The role of milk-derived antimicrobial lipids as antiviral and antibacterial agents. In: Immunology of Milk and the Neonate. Edited by J. Mestecky et al. Plenum Press, 1991, pp. 159-165; C. E. Isaacs et al., Addition of lipases to infant formulas produces antiviral and antibacterial activity, J. Nutr. Biochem. 3, 304-308, 1992; C. E. Isaacs et al. Antimicrobial activity of lipids added to human milk, infant formula, and bovine milk, Nutr. Biochem. 6, 362-366, 1995) where the active lipids are free fatty acids and monoglycerides which are released from triglycerides in the milk-by-milk lipases or lipases of the gastrointestinal tract.

[0009] The virucidal effect of purified lipids has been studied in cell culture media (H. Thormar, C. E. Isaacs et al., Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. Antimicr. Agents Chemother. 31, 27-31, 1987; H. Thormar, C. E. Isaacs et. al., Inactivation of visna virus and other enveloped viruses by free fatty acids and monoglycerides. Ann. N.Y. Acad. Sci. 724, 465-471, 1994).

[0010] Treating helminth or parasite eggs that are attached to a body surface, such as targeting schistosomiasis eggs, specifically, in the vagina is described in U.S. Patent No. 10,857,151, issued in December 2020 to Villya LLC. This patent describes topical formulations of praziquantel, a drug commonly used to treat schistosomiasis, designed for local application to the female genital tract. This patent discloses formulations, designed for insertion into the vagina or uterus using applicators or tampons, allowing direct treatment of schistosomiasis lesions and eggs in the genital tract. According to the disclosure the active medicine, praziquantel, is combined with pharmaceutically acceptable vehicles such as gels, creams, foams, or jellies, which help the drug adhere to the mucosal surfaces and enhance its effectiveness, in dosages ranging from 200 to 1,000 mg of praziquantel, with recommendations for administration via vaginal applicators or intrauterine catheters, depending on the location of the infection.

[0011] SUMMARY OF THE INVENTION

[0012] This invention is based on inventors' finding of a surprising and substantial effect of specific lipid compounds and formulations thereof on parasite eggs or oocysts. The eggs and oocysts of insects are more resistant to different antimicrobial treatmentsP16103PC00

[0013] than bacteria, so many anti-bacterial treatments are not effective when trying to kill these parasite eggs and oocysts. Specifically, the inventor has found and established that lipids, such as monoglycerides and / or respective degradation products, their fatty acids, are able to disintegrate parasite eggs and oocysts, when administered to or on these parasite eggs and / or oocysts. These lipids (monoglycerides and / or fatty acids) are, thereby, able to disintegrate eggs and / or oocysts in the nasal, ocular, otal, pharynx, larynx, sinuses, oral cavity, vaginal or dermal surface of a mammal.

[0014] The microbicidal activities of lipids and their potential applications for killing microorganisms in bodily fluids have been described in U.S. Patents No. 4,997,851 and 5,434,182. Their application for disinfecting contact lenses is described in U.S. Pat. No. 5,624,958 and their application for counteracting infection of mucosa or skin in published US patent application No. 10 / 408235.

[0015] According to the present invention, it has been found that certain lipids, in a concentration range from 0.05 to 5%, preferably in the range 0.5-3%, are capable of disintegrating parasite eggs and oocysts, organisms that are much more resistant than bacteria towards chemical treatment with compounds like chlorine and other toxins.

[0016] Accordingly, in one aspect this disclosure provides a lipid for use to treat or prevent parasitic infection of a mammal subject, in particular by killing parasite eggs or oocysts in or on the mammal, or on an exterior surface that a mammal may come in contact with. The lipid is preferably selected from glycerol monocaprate, glycerol monocaprylate, glycerol monolaurate, propylene glycol monocaprate, propylene glycol monocaprylate, propylene glycol monolaurate, glycerol dicaprin, glycerol dicaprylate, glycerol dilaurate, glycerol tricaprin, glycerol tricaprylate, glycerol trilaurate, octylglycerol, monomyristin, monopalmitolein, monoolein, propylene glycol monocaprylate, propylene glycol monolaurate, and any combination thereof. The lipid may be formulated in an amount in the range from about 0.1 to about 5 % wt dissolved or suspended in a composition, wherein the composition comprises optionally one or more C8-C12 fatty acid in a concentration in the range from about 0.1 to about 3 %wt, and a pharmaceutically acceptable vehicle. The composition may in some embodiments be in liquid, semisolid and / or solid form. In some embodiments the composition may be a liquid formulation in a form selected from the group consisting of solution, ointment, spray, aerosol, mist, drops, creme, gel, suppository, and vagitory.

[0017] The lipid for use according to the invention may be formulated for administration selected from topical administration to mammal skin, administration to oral cavity,P16103PC00

[0018] administration to nasal mucosa, ocular administration, otal administration, administration pharynx, administration larynx, administration sinuses, vaginal administration, rectal administration, and topical administration to nails, but also formulated for surface administration such as but not limited to cloths, and surfaces that people and animals may touch, such as but not limited to floors, tables tops and sinks.

[0019] In another aspect the disclosure provides a pharmaceutical anti-parasitic lipid formulation for use to treat or prevent parasitic infection of a mammal subject, such as a human, the formulation comprising:

[0020] an anti-parasitically biologically active lipid in a concentration in the range from about 0.1 to about 5%, dissolved or suspended in the formulation, preferably within the range from about 0.3 to about 3%; optionally a C8-C12 fatty acid in a concentration in the range from about 0.1 to about 4%; and a pharmaceutically acceptable vehicle.

[0021] As understood from the description above, the formulation is in preferred embodiments intended and applicable for use to treat or prevent parasitic infection of a mammal subject by killing parasite eggs or oocysts infested in or on the mammal.

[0022] The anti-parasitically active lipid in the composition is preferably any of the above mentioned, that is one or more of anti-parasitically active lipid is selected from the group consisting of glycerol monocaprate, glycerol monocaprylate, glycerol monolaurate, propylene glycol monocaprate, propylene glycol monocaprylate, propylene glycol monolaurate, glycerol dicaprin, glycerol dicaprylate, glycerol dilaurate, glycerol tricaprin, glycerol tricaprylate, glycerol trilaurate, octylglycerol, monomyristin, monopalmitolein, monoolein, propylene glycol monocaprylate, propylene glycol monolaurate, and any combination thereof.

[0023] The particular formulation or composition (in the present context, these terms are synonymous) may in some embodiments contain the lipid dissolved or suspended in the formulation together with in the range of 0.2-5 wt%, preferably in the range 0.5-3 wt% ethanol, allowing the lipid to exert its killing effect in the aqueous environment prevailing at mammalian surfaces such as the nasal, ocular, otal, pharynx, larynx, sinuses, oral cavity, vaginal or dermal surface. In some embodiments the ethanol is present in the formulation in a range from 0.2 wt%, or from 0.3 wt% or from 0.4 wt%, or from 0.5 wt%, to 5 wt%, or to 4 wt% or to 3 wt% or to 2.5 wt% or to 2 wt%.P16103PC00

[0024] In some embodiments one or more fatty acid is comprised in the formulation. If fatty acids are used in the formulation, they are in the range of 0.1-4 wt%, preferably in the range 0.2-4 wt% and more preferably in the range 0.5-3 wt%, but can be in a range from 0.1 wt% or from 0.2 wt% or from 0.3 wt% or from 0.4 wt% or from 0.5 wt%, to 4 wt%, or to 3.5 wt%, or to 3 wt%. Fatty acids have been found by the inventor to have surprising effects of the antimicrobial effects induced by the microbicidal lipids of the invention. The formulation containing C8-C12 fatty acids and lipids together had surprisingly powerful microbicidal effects when combined with microbicidal lipids used to treat or prevent infections infection in the nasal, ocular, otal, pharynx, larynx, sinuses, oral cavity, vaginal or dermal surface of a mammal, caused by parasite eggs and / or oocysts. The C8-C12 fatty acid is in some embodiments selected from capric acid, caprylic acid, lauric acid and any mixture thereof.

[0025] The composition of the disclosure is in some embodiments in a form selected from liquid, semisolid and / or solid form, preferably a liquid formulation in a form selected from the group consisting of solution, ointment, spray, aerosol, mist, drops, creme, gel, suppository, and vagitory. In some embodiments the composition further comprises methoxy-polyethylene glycol as a pharmaceutically acceptable formulation excipient.

[0026] A further aspect of the disclosure relates to a method for preventing and / or treating infections caused by parasite eggs and / or oocysts in skin or mucosal membranes, in particular infection in the nasal, ocular, otal, pharynx, larynx, sinuses, oral cavity, vaginal or dermal surface, comprising administering an effective amount of the formulation which contains at least one lipid as an active ingredient as described herein and preferably formulated as described above. Thus as understood from the above, the method of the invention may in particular comprise killing parasite eggs or oocysts infested in or on the mammal.

[0027] In another aspect the disclosure provides a method of preventing parasitic infection comprising treating a surface such as from textiles, including clothes and bed linen, table tops, sinks, floors, door handles, with an antiparasitic formulation capable of killing eggs and / or oocysts of parasitic insects, the formulation comprising an anti-parasitically active lipid, in particular a lipid as described above, in a concentration in the range from about 0.1 to about 5 wt%, dissolved or suspended in the formulation, preferably within the range from about 0.3 to about 3 wt%, optionally a C8-C12 fatty acid in a concentration in the range from about 0.1 to about 3%, and a pharmaceutically acceptable vehicle.P16103PC00

[0028] DETAILED DESCRIPTION OF THE INVENTION

[0029] The term "antiparasitic lipid" is used herein to designate a lipid, which is capable of killing parasite eggs and / or oocysts. As explained above, antiparasitic lipids have been shown to disintegrate and kill parasite eggs and / or oocysts, so that these organisms will no longer be able to survive.

[0030] The formulation of the invention is generally a liquid, semi-liquid or solid formulation. The presently preferred formulation comprises a solution, an emulsion, a suspension, a viscous fluid, or semisolid such as but not limited to a gel or gel-like composition, in particular a hydrogel, or a suppository or vagitory. The formulation is preferably a formulation that can be applied to and remain in contact with the nasal, ocular, otal, pharynx, larynx, sinuses, oral cavity, vaginal or dermal surface of a mammal. For many mucosal surfaces, an aqueous solution is useful.

[0031] The aqueous solution in the formulation is preferably provided by having water as a constituent, normally a major constituent, of the formulation, but it is contemplated that the aqueous solution may also in certain cases be provided with various excipients such as but not limited to solubilizers, bioadhesive agents and surfactants.

[0032] Preferably, the antiparasitic lipid component comprises a monoester of a C8-C12 fatty acid chain, such as but not limited to monocaprin and monolaurin, where the fatty acid may be located in position 1, having either S- isomer or R-isomer or combination thereof. Monoester (C8-C12) having the fatty acid in position 2 is also used according to the invention and the lipid may additionally comprise a minor amount of diglycerides, triglycerides and in order to achieve improved effect the formulation may optionally comprise pure (free) respective fatty acid(s).

[0033] In case fatty acid(s) is added to a formulation containing the antiparasitic lipid (e.g. glyceride) as component(s) present in an amount of at least 0.2 wt% or into which the antiparasitic lipids or glycerides are to be added. Also, in case ethanol is present in the final formulation it is preferably in a concentration within a range from about 0.1%, such as from about 0.2%, such as from about 0,3%, such as from about 0,4%, such as from about 0,5%, to about 4%, such as to about 3%, such as to about 2,5%, such as, but not limited to, about 0,2%, about 0,3%, about 0,4%, about 0,5%, about 0,8%, about 1,0%, about 1,2%, about 1,5%, about 1,7%, about 2%, about 2,25, and about 2,5%.P16103PC00

[0034] Unless otherwise specified, all weight percents are weight / weight percentages based on the total weight of a "ready to use" or "as used" composition.

[0035] The pharmaceutical composition containing lipid(s) of the invention comprise a biologically active lipid selected from the group consisting of but not limited to glycerol monocaprate, glycerol monocaprylate, glycerol monolaurate, propylene glycol monocaprate, propylene glycol monocaprylate, glycerol dicaprin, glycerol dicaprylate, glycerol dilaurate, glycerol tricaprin, glycerol tricaprylate, glycerol trilaurate, octylglycerol, monomyristin, monopalmitolein, monoolein, propylene glycol monolaurate, coca butter, and combinations thereof

[0036] The active lipid ingredient, such as any of the above mentioned, is typically and preferably in a concentration within a range from about 0.01%, such as from about 0,05%, such as from about 0.1%, such as from about 0.2%, to about 5%, such as to about 2.5% or 2%, such as to about 1.5% such as to about 1%. The selected concentration may depend on the intended delivery form (vagitories, suppositories, ointment, solution, spray, gel, etc.) and intended location of application, as further described herein. In some embodiments the lipid substance is present in a concentration of about 0.1%, or about 0.2%, or about 0.25%, or about 0.3%, or about 0.4%, or about 0.5%, or about 0.6% or about 0.7% or about 0.8%, or about 0.9% or about 1.0%.

[0037] The antimicrobial lipids and the formulations of the present invention are suitably used to kill one or more of the following parasite eggs and oocysts (but not limited to those): (a) helminths (Worms) that release eggs such as but not limited to trematodes (Flukes) such as but not limited to Schistosoma spp. (S. haematobium, S. mansoni, S. japonicum), Fasciola hepatica, Clonorchis sinensis, Paragonimus westermani, Cestodes (Tapeworms) such as but not limited to Taenia solium, Taenia saginata, Hymenolepis nana, Diphyllobothrium latum’, Nematodes (Roundworms) such as but not limited to Ascaris lumbricoides, Trichuris trichiura, Enterobius vermicularis, Ancylostoma duodenale, Necator americanus', (b) protozoa that release cysts and / or oocysts such as but not limited to Entamoeba histolytica, Giardia lamblia, Cryptosporidium parvum, and Toxoplasma gondii.

[0038] Of course, salts, metabolic precursors, derivatives and mixtures of these antiparasitic lipids may also be used where desired, in accordance with the invention.P16103PC00

[0039] As has already been pointed out the active substance is in certain embodiments, depending on the intended use and application site, present in an effective amount within a total volume of less than 10 mL, preferably less than 7000 pL, for certain surfaces the total volume of less than 5000 pL are preferable, or more preferably within the range 50-2000 pL. Accordingly, the formulation of the invention is in some embodiments provided in a dosage unit providing a unit dose within the above mentioned ranges and amounts.

[0040] In some embodiments the pharmaceutical preparation additionally comprises minor proportions of one or more substance(s) selected from the group consisting of absorption promoters, water absorbing polymers, microspheres, oils, emulsions, liposomes, substances that inhibit enzymatic degradation, alcohols, organic solvents, water, surfactants, hydrophobic agents, pH-controlling agents, preservatives and osmotic pressure controlling agents, cyclodextrins and propellants or mixtures thereof.

[0041] The invention also relates to a method for treatment of animals such as pets and corresponding compositions for use: for example but not limited to dogs, cats, rabbits, guinea pigs, farm animals: such as but not limited to horses, sheep, pigs, cattle, chicken or captured wild animals, such as but not limited to rhinoceros such as Ceratotherium simum, Diceros bicornis, Rhinoceros unicornis, Rhinoceros sondaicus, Dicerorhinus sumatrensis, lions, tigers, jaguars, elephants, giraffes, hippos with an effective amount of a biologically active lipid and fatty acid, wherein the dosage unit quantity of a biologically active substance is applied to a surface of the animal to be treated in a formulation according to the invention. The volume administered to each animal, administration site, should preferably be calculated based on the relative human / animal surface area that needs to be exposed.

[0042] The invention also relates to a method for treating surfaces such as but not limited to cloths, tables, floors, walls, sinks and other surfaces people touch or home and / or industrial surfaces, walls, tables, floors, equipment, instruments or as an aerosol where biological fluid containing these parasite eggs and / or oocyst has contaminated the surface and need to be cleaned.

[0043] The surface such as but not limited to the skin or the mucosal membrane to which the pharmaceutical preparation of the invention is administered may be any mucosal membrane of the mammal to which the biologically active lipid is to be given, e.g. onP16103PC00

[0044] the skin or in the nose, sinuses, vagina, eye, ear, mouth, oral cavity, pharynx, genital tract, lungs, gastrointestinal tract, or rectum, preferably the mucosa of the vagina, nose, sinuses mouth (buccal, gingual, sublingual or to the hard palate), pharynx, larynx, uterus and the air. Thepharmaceutical preparation may also be administered to various parts of the skin, hair and the nails.

[0045] The pharmaceutical compositions of the invention may be administered in the form of a sublingual lozenge or troche or a buccal, pharynx, ear, sinus or nasal spray or drops in the form of a solution, micelles, nanoemulsion, optionally in water and / or together with polymers such as methoxy polyethylene glycol, polyethylene glycol or propylene glycol optionally in the form of slightly viscous solution for the skin or the vagina, or as a solid or semisolids in the form of a suppository or vagitory, or as dermal products for infected skin, hair or nails.

[0046] If desired, the pharmaceutical compositions of the present invention can optionally include additional compounds to enhance the solubility of the therapeutic agent (a solubilizer). Examples of such compounds include but are not limited to: alcohols and polyols, such as but not limited to isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000 or tetrahydrofurfuryl alcohol PEG ether (glycofurol, available commercially from BASF under the trade name Tetraglycol); amides, such as 2-pyrrolidone, 2-piperidone, .epsilon. -caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide, and polyvinylpyrrolidone; esters, such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, .epsilon. -caprolactone and isomers thereof, .delta. -valerolactone and isomers thereof, .beta. -butyrolactone and isomers thereof; and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide (Arlasolve DMI (ICI)), N-methyl pyrrolidones (Pharmasolve (ISP)), monooctanoin, diethylene glycol monoethyl ether (available from Gattefosse under the trade name Transcutol), and water.

[0047] For the manufacturing of suppositories or vagitories or in case there is a need forP16103PC00

[0048] additional fat, the formulation may additionally contain one or more substance from cocoa butter, fatty acid glycerides such as di- and / or triglycerides, high molecular weight polyethylene glycol, castor oil, paraffin oil, and adeps solidus.

[0049] Mixtures of solubilizers are also within the scope of the invention and are accordingly comprised in the formulation of the invention in some embodiments. Except as indicated, these compounds are readily available from standard commercial sources.

[0050] Preferred solubilizers include triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, methoxy-polyethylene glycol 350-1500, polyethylene glycol 200-1000, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, mPEG 350-550, PEG-300-400, glycofurol and propylene glycol.

[0051] The amount of solubilizer that can be included in compositions of the present invention is not particularly limited. Of course, when such compositions are ultimately administered to a person or a patient, the amount of a given solubilizer is limited to a bioacceptable amount, which is readily determined by one of skill in the art. In some circumstances, it may be advantageous to include amounts of solubilizers far in excess of bioacceptable amounts, for example, to maximize the concentration of the therapeutic agent, with excess solubilizer removed prior to providing the composition to a patient using conventional techniques, such as distillation or evaporation. Typically, the solubilizer will be present in an amount of about 1% to about 100%, more typically about 5% to about 75% by weight or about 5% to about 25% by weight.

[0052] Other excipients that may be needed in the formulation are following: pH-controlling agents, such as, nitric acid, phosphoric acid, or acetic acid, citrate; preservatives and osmotic pressure controlling agents, such as glycerol, sodium chloride, methyl paraoxybenzoate, or benzoic acid; powder compositions, such as, alfa-, beta- and gamma-cyclodextrins, cellulose and derivatives; microspheres, nanospheres, virosomes, proteosomes, liposomes and emulsion compositions, such as, starch, albumin, gelatine, or lecithins or lysoleciythins; microencapsulated formulations; propellants such as butane; water.P16103PC00

[0053] Based on experiments presented in the Examples, it is presently preferred that the lipid is selected from capric acid, caprylic acid, lauric acid and / or mixtures thereof, as these have shown very high microbicidal activities with synergy together with monoglycerides such as monocaprin, monolaurin and monocaprylin. The presently most preferred fatty acid is capric acid, lauric acid and caprylic acid according to the invention.

[0054] In the formulations used in the method of the present invention, the microbicidal lipid or lipids is / are preferably present in the formulation in a total concentration within a range from about 1 millimolar, such as from about 2 millimolar, or from about 5 millimolar, to about 40 millimolar, such as to about 30 millimolar, or to about 25 millimolar, preferably in a concentration of about 5 to 30 millimolar.

[0055] Examples of diseases that can be treated or prevented by the formulations and method according to the invention are following such as but not limited to schistosomiasis, fascioliasis (liver fluke), clonorchiasis (liver fluke), paragonimiasis (lung fluke), taeniasis, cysticercosis, hymenolepiasis, diphyllobothriasis (fish tapeworm), ascariasis, trichuriasis (whipworm), pinworm infection, hookworm infection, amoebiasis, giardiasis, cryptosporidiosis, oocysts, tissue cysts and / or toxoplasmosis.

[0056] EXAMPLES

[0057] Example 1

[0058] Formulations were made to be used as vaginal ointment or as a dermal ointment to prevent and / or fight diseases caused by parasite eggs or oocysts according to the invention may contain following formulation:

[0059] Formulation

[0060] Component I II III IV Monocaprin 1% 1 10 / / o JO / / o Z 90 / / o Monolaurin 1% 1 10 / / o 90 / / o Z 90 / / o Capric acid 0% 0.5% 0% 1% Lauric acid 0% 0.5% 0% 0% PAF*

[0061]

[0062] 98% 97% 94%

[0063] 95%

[0064] * Pharmaceutically Acceptable Formulation

[0065] Here the monocaprin and monolaurin are dissolved in the PAF using vortex, ultrasound, heat and / or other standard methods, whereafter the mixture is mixed well together using standard methods to receive a homogenious transparent solution.P16103PC00

[0066] Parasite egg and oocyst challenge test were made. The parasite Shistosomiasis was implanted in mice and allowed to grow and mature, until the parasite started producing eggs. These eggs were harvested and tested towards the formulation. The results were that the composition was able to disintegrate the eggs.

[0067] Example 2

[0068] Formulations were made to be used as surface spray or drops to disintegrate parasite eggs and / or oocyst on cloths, surfaces, even hair and skin that are contaminated with eggs and / or oocyst from parasites according to the invention may contain following formulation:

[0069] Formulation

[0070] Component I

[0071]

[0072] Monocaprin 0.2-3% 0.2-3% Monolaurin 0.2-3% 0.2-3% Capric acid 0-2% 0-2% Lauric acid 0-2% 0-2% PAF* q.s. q.s.

[0073] * Pharmaceutically Acceptable Formulation

[0074] Test were carried out on parasite eggs and oocysts, as described in Example 1. Positive results were obtained, showing that the composition was able to disintegrate the eggs.

[0075] Selected specific embodiments

[0076] 1. A pharmaceutical anti-parasitic lipid composition for use to treat or prevent parasitic infection of a mammal subject, comprising:

[0077] a) an anti-parasitically active lipid in a concentration in the range from about 0.1 to about 5%, dissolved or suspended in the formulation, preferably within the range from about 0.3 to about 3%, b) optionally a C8-C12 fatty acid in a concentration in the range from about 0.1 to about 3%, and

[0078] c) a pharmaceutically acceptable vehicle.P16103PC00

[0079] 2. The pharmaceutical anti-parasitic lipid composition according to embodiment 1 , for use to treat or prevent parasitic infection of a mammal subject by killing parasite eggs or oocysts infested in or on the mammal.

[0080] 3. The pharmaceutical anti-parasitic lipid composition according to embodiment 1 or 2, wherein the anti-parasitically active lipid is selected from the group consisting of glycerol monocaprate, glycerol monocaprylate, glycerol monolaurate, propylene glycol monocaprate, propylene glycol monocaprylate, propylene glycol monolaurate, glycerol dicaprin, glycerol dicaprylate, glycerol dilaurate, glycerol tricaprin, glycerol tricaprylate, glycerol trilaurate, octylglycerol, monomyristin, monopalmitolein, monoolein, propylene glycol monocaprylate, propylene glycol monolaurate, and any combination thereof.

[0081] 4. The pharmaceutical anti-parasitic lipid composition according to any of embodiments 1 to 3, comprising the C8-C12 fatty acid, which is selected from capric acid, caprylic acid, lauric acid and any mixture thereof.

[0082] 5. The pharmaceutical anti-parasitic lipid composition according to embodiment 1 or 2, wherein the composition is in a form selected from liquid, semisolid and / or solid form, preferably a liquid formulation in a form selected from the group consisting of solution, ointment, spray, aerosol, mist, drops, creme, gel, suppository, and vagitory.

[0083] 6. The pharmaceutical anti-parasitic composition according to any of the preceding embodiments, further comprising methoxy-polyethylene glycol as a pharmaceutically acceptable formulation excipient.

[0084] 7. The pharmaceutical anti-parasitic composition according to embodiment 6, wherein said methoxypolyethylene glycol comprises mPEG350 and / or mPEG550, and preferably Carbovax™ Sentry™ mPEG 350 or Carbovax™ Sentry™ mPEG 550.

[0085] 8. The pharmaceutical anti-parasitic composition according to any of the preceding embodiments, further comprising one or more excipient selected from the group consisting of absorption promoters, water absorbing polymers, microspheres, oils, emulsions, liposomes, substances that inhibit enzymatic degradation, alcohols, organic solvents, water, surfactants, hydrophobicP16103PC00

[0086] agents, pH-controlling agents, preservatives and osmotic pressure controlling agents, cyclodextrins and propellants or mixtures thereof.

[0087] 9. The pharmaceutical anti-parasitic composition according to any of the preceding embodiments, formulated for administration selected from topical administration to mammal skin, administration to oral cavity, administration to nasal mucosa, ocular administration, otal administration, administration pharynx, administration larynx, administration sinuses, vaginal administration, rectal administration, and topical administration to nails, surface administration to cloths, and surfaces people and animals touch such as but not limited to floors and sinks.

[0088] 10. The pharmaceutical anti-parasitic composition according to any of the preceding claims which is a liquid formulation, provided in a dosage unit of less than or about 10 mL, preferably less than 3,0 mL, more preferably less than 2,0 mL and even more preferably in a volume within the range from about 50 to about 1000 pL.

[0089] 11. The pharmaceutical anti-parasitic composition according to any of the preceding claims, which is an aqueous formulation, preferably a hydrogel formulation.

[0090] 12. A lipid for use to treat or prevent parasitic infection of a mammal subject by killing parasite eggs or oocysts in or on the mammal.

[0091] 13. The lipid for use according to claim 11, selected from the group consisting of glycerol monocaprate, glycerol monocaprylate, glycerol monolaurate, propylene glycol monocaprate, propylene glycol monocaprylate, propylene glycol monolaurate, glycerol dicaprin, glycerol dicaprylate, glycerol dilaurate, glycerol tricaprin, glycerol tricaprylate, glycerol trilaurate, octylglycerol, monomyristin, monopalmitolein, monoolein, propylene glycol monocaprylate, propylene glycol monolaurate, and any combination thereof.

[0092] 14. The lipid for use according to claim 12 or 13, formulated in an amount in the range from about 0.1 to about 5 % wt in a composition, wherein the composition comprises optionally one or more C8-C12 fatty acid in a concentration in theP16103PC00

[0093] range from about 0.1 to about 3 %wt, and a pharmaceutically acceptable vehicle.

[0094] 15. The lipid for use according to claim 14, wherein the composition is in liquid, semisolid and / or solid form.

[0095] 16. The lipid for use according to claim 15, wherein the composition is a liquid formulation in a form selected from the group consisting of solution, ointment, spray, aerosol, mist, drops, creme, gel, suppository, and vagitory.

[0096] 17. The lipid for use according to any of claims 14 to 16, formulated for administration selected from topical administration to mammal skin, administration to oral cavity, administration to nasal mucosa, ocular administration, otal administration, administration pharynx, administration larynx, administration sinuses, vaginal administration, rectal administration, and topical administration to nails, surface administration to cloths, and surfaces people and animals touch such as but not limited to floors, table tops and sinks.

[0097] 18. Use of an antiparasite lipid in the treatment or prevention of a disease or condition in a mammal such as a human, selected from infection in the nasal, ocular, otal, pharynx, larynx, sinuses, oral cavity, vaginal or dermal surface of a mammal, caused by parasite eggs and / or oocyte, wherein the antimiparasite active lipid is formulated in a formulation comprising in the range from about 0.1% to about 5% of said lipid, said formulation optionally further comprising a fatty acid in a concentration in the range from about 0.1% to about 5%, in a pharmaceutically acceptable vehicle.

[0098] 19. A method of treating or preventing a parasitic infection of a mammal subject by killing parasite eggs or oocysts in or on the mammal comprising administering to said mammal an anti-parasitically active lipid.

[0099] 20. A method of treating or preventing a parasitic infection of a mammal subject comprising administering to said mammal a composition comprising:P16103PC00

[0100] a) an anti-parasitically active lipid in a concentration in the range from about 0.1 to about 5%, dissolved or suspended in the formulation, preferably within the range from about 0.3 to about 3%,

[0101] b) optionally a C8-C12 fatty acid in a concentration in the range from about 0.1 to about 3%, and

[0102] c) a pharmaceutically acceptable vehicle.

[0103] 21. The method according to embodiment 19 or 20, wherein the anti-parasitically active lipid is selected from the group consisting of glycerol monocaprate, glycerol monocaprylate, glycerol monolaurate, propylene glycol monocaprate, propylene glycol monocaprylate, propylene glycol monolaurate, glycerol dicaprin, glycerol dicaprylate, glycerol dilaurate, glycerol tricaprin, glycerol tricaprylate, glycerol trilaurate, octylglycerol, monomyristin, monopalmitolein, monoolein, propylene glycol monocaprylate, propylene glycol monolaurate, and any combination thereof.

[0104] 22. The method according to any of embodiments 19 to 21, wherein said composition comprises said C8-C12 fatty acid, which is selected from capric acid, caprylic acid, lauric acid and any mixture thereof.

[0105] 23. The method according to any of embodiments 19 to 22, wherein the composition is in liquid, semisolid and / or solid form. , preferably a liquid formulation in a form selected from the group consisting of solution, ointment, spray, aerosol, mist, drops, creme, gel, suppository, and vagitory.

[0106] 24. The method according to any of embodiments 19 to 23, comprising administering the composition suitably formulated via an administration mode selected from from topical administration to mammal skin, administration to oral cavity, administration to nasal mucosa, ocular administration, otal administration, administration pharynx, administration larynx, administration sinuses, vaginal administration, rectal administration, and topical administration to nails.

[0107] 25. A method of preventing parasitic infection comprising treating a surface such as from textiles, including clothes and bed linen, table tops, sinks, floors, door handles, with an antiparasitic composition capable of killing eggs and / or oocysts of parasitic insects, the composition comprisingP16103PC00

[0108] an anti-parasitically active lipid in a concentration in the range from about 0.1 to about 5%, dissolved or suspended in the formulation, preferably within the range from about 0.3 to about 3%,

[0109] optionally a C8-C12 fatty acid in a concentration in the range from about 0.1 to about 3%, and

[0110] a pharmaceutically acceptable vehicle.

[0111] 26. The method according to embodiment 25, wherein the anti-parasitically active lipid is selected from the group consisting of glycerol monocaprate, glycerol monocaprylate, glycerol monolaurate, propylene glycol monocaprate, propylene glycol monocaprylate, propylene glycol monolaurate, glycerol dicaprin, glycerol dicaprylate, glycerol dilaurate, glycerol tricaprin, glycerol tricaprylate, glycerol trilaurate, octylglycerol, monomyristin, monopalmitolein, monoolein, propylene glycol monocaprylate, propylene glycol monolaurate, and any combination thereof.

[0112] 27. The method according to embodiment 25 wherein said composition comprises said C8-C12 fatty acid, which is selected from capric acid, caprylic acid, lauric acid and any mixture thereof.

Claims

P16103PC00CLAIMS1. A pharmaceutical anti-parasitic lipid composition for use to treat or prevent parasitic infection of a mammal subject, comprising:d) an anti-parasitically active lipid in a concentration in the range from about 0.1 to about 5 %wt, dissolved or suspended in the formulation, preferably within the range from about 0.3 to about 3 %wt, e) optionally a C8-C12 fatty acid in a concentration in the range from about 0.1 to about 3 %wt, andf) a pharmaceutically acceptable vehicle.

2. The pharmaceutical anti-parasitic lipid composition according to claim 1 , for use to treat or prevent parasitic infection of a mammal subject by killing parasite eggs or oocysts infested in or on the mammal.

3. The pharmaceutical anti-parasitic lipid composition according to claim 1 or 2, wherein the anti-parasitically active lipid is selected from the group consisting of glycerol monocaprate, glycerol monocaprylate, glycerol monolaurate, propylene glycol monocaprate, propylene glycol monocaprylate, propylene glycol monolaurate, glycerol dicaprin, glycerol dicaprylate, glycerol dilaurate, glycerol tricaprin, glycerol tricaprylate, glycerol trilaurate, octylglycerol, monomyristin, monopalmitolein, monoolein, propylene glycol monocaprylate, propylene glycol monolaurate, and any combination thereof.

4. The pharmaceutical anti-parasitic lipid composition according to any of claims 1 to 3 comprising the C8-C12 fatty acid, which is selected from capric acid, caprylic acid, lauric acid and any mixture thereof.

5. The pharmaceutical anti-parasitic lipid composition according to any of the preceding claims, wherein the composition is in a form selected from liquid, semisolid and / or solid form, preferably a liquid formulation in a form selected from the group consisting of solution, ointment, spray, aerosol, mist, drops, creme, gel, suppository, and vagitory.

6. The pharmaceutical anti-parasitic composition according to any of the preceding claims, further comprising methoxy-polyethylene glycol as a pharmaceutically acceptable formulation excipient.P16103PC007. The pharmaceutical anti-parasitic composition according to claim 6, wherein said methoxypolyethylene glycol comprises mPEG350 and / or mPEG550, and preferably Carbovax™ Sentry™ mPEG 350 or Carbovax™ Sentry™ mPEG 550.

8. The pharmaceutical anti-parasitic composition according to any of the preceding claims, further comprising one or more excipient selected from the group consisting of absorption promoters, water absorbing polymers, microspheres, oils, emulsions, liposomes, substances that inhibit enzymatic degradation, alcohols, organic solvents, water, surfactants, hydrophobic agents, pH-controlling agents, preservatives and osmotic pressure controlling agents, cyclodextrins and propellants or mixtures thereof.

9. The pharmaceutical anti-parasitic composition according to any of the preceding claims, formulated for administration selected from topical administration to mammal skin, administration to oral cavity, administration to nasal mucosa, ocular administration, otal administration, administration pharynx, administration larynx, administration sinuses, vaginal administration, rectal administration, and topical administration to nails, surface administration to cloths, and surfaces people and animals touch such as but not limited to floors and sinks.

10. The pharmaceutical anti-parasitic composition according to any of the preceding claims which is a liquid formulation, provided in a dosage unit of less than or about 10 mL, preferably less than 3,0 mL, more preferably less than 2,0 mL and even more preferably in a volume within the range from about 50 to about 1000 pL.

11. The pharmaceutical anti-parasitic composition according to any of the preceding claims, which is an aqueous formulation, preferably a hydrogel formulation.

12. A lipid for use to treat or prevent parasitic infection of a mammal subject by killing parasite eggs or oocysts in or on the mammal.P16103PC0013. The lipid for use according to claim 11, selected from the group consisting of glycerol monocaprate, glycerol monocaprylate, glycerol monolaurate, propylene glycol monocaprate, propylene glycol monocaprylate, propylene glycol monolaurate, glycerol dicaprin, glycerol dicaprylate, glycerol dilaurate, glycerol tricaprin, glycerol tricaprylate, glycerol trilaurate, octylglycerol, monomyristin, monopalmitolein, monoolein, propylene glycol monocaprylate, propylene glycol monolaurate, and any combination thereof.

14. The lipid for use according to claim 12 or 13, formulated in an amount in the range from about 0.1 to about 5 % wt in a composition, wherein the composition comprises optionally one or more C8-C12 fatty acid in a concentration in the range from about 0.1 to about 3 %wt, and a pharmaceutically acceptable vehicle.

15. The lipid for use according to claim 14, wherein the composition is in liquid, semisolid and / or solid form.

16. The lipid for use according to claim 15, wherein the composition is a liquid formulation in a form selected from the group consisting of solution, ointment, spray, aerosol, mist, drops, creme, gel, suppository, and vagitory.

17. The lipid for use according to any of claims 14 to 16, formulated for administration selected from topical administration to mammal skin, administration to oral cavity, administration to nasal mucosa, ocular administration, otal administration, administration pharynx, administration larynx, administration sinuses, vaginal administration, rectal administration, and topical administration to nails, surface administration to cloths, and surfaces people and animals touch such as but not limited to floors, table tops and sinks.

18. Use of an antiparasite lipid in the treatment or prevention of a disease or condition in a mammal such as a human, selected from infection in the nasal, ocular, otal, pharynx, larynx, sinuses, oral cavity, vaginal or dermal surface of a mammal, caused by parasite eggs and / or oocyte, wherein the antimiparasite active lipid is formulated in a formulation comprising in the range from about 0.1 %wt to about 5 %wt of said lipid, said formulation optionally furtherP16103PC00comprising a fatty acid in a concentration in the range from about 0.1 %wt to about 5 %wt, in a pharmaceutically acceptable vehicle.

19. A method of treating or preventing a parasitic infection of a mammal subject by killing parasite eggs or oocysts in or on the mammal comprising administering to said mammal an anti-parasitically active lipid.

20. The method according to claim 19, wherein the anti-parasitically active lipid is formulated in a composition comprising:a) the anti-parasitically active lipid in a concentration in the range from about 0.1 to about 5 wt%, dissolved or suspended in the composition, preferably within the range from about 0.3 to about 3 wt%,b) optionally a C8-C12 fatty acid in a concentration in the range from about 0.1 to about 3 wt%, andc) a pharmaceutically acceptable vehicle.

21. The method according to claim 19 or 20, wherein the anti-parasitically active lipid is selected from the group consisting of glycerol monocaprate, glycerol monocaprylate, glycerol monolaurate, propylene glycol monocaprate, propylene glycol monocaprylate, propylene glycol monolaurate, glycerol dicaprin, glycerol dicaprylate, glycerol dilaurate, glycerol tricaprin, glycerol tricaprylate, glycerol trilaurate, octylglycerol, monomyristin, monopalmitolein, monoolein, propylene glycol monocaprylate, propylene glycol monolaurate, and any combination thereof.

22. The method according to any of claims 19 to 21, wherein said composition comprises said C8-C12 fatty acid, which is selected from capric acid, caprylic acid, lauric acid and any mixture thereof.

23. The method according to any of claims 19 to 22, wherein the composition is in a form selected from liquid, semisolid and / or solid form, preferably a liquid formulation in a form selected from the group consisting of solution, ointment, spray, aerosol, mist, drops, creme, gel, suppository, and vagitory.

24. The method according to any of claims 19 to 23, comprising administering the composition suitably formulated via an administration mode selected fromP16103PC00topical administration to mammal skin, administration to oral cavity, administration to nasal mucosa, ocular administration, otal administration, administration pharynx, administration larynx, administration sinuses, vaginal administration, rectal administration, and topical administration to nails.

25. A method of preventing parasitic infection comprising treating a surface such as from textiles, including clothes and bed linen, table tops, sinks, floors, door handles, with an antiparasitic formulation capable of killing eggs and / or oocysts of parasitic insects, the formulation comprisingan anti-parasitically active lipid in a concentration in the range from about 0.1 to about 5%, dissolved or suspended in the formulation, preferably within the range from about 0.3 to about 3%,optionally a C8-C12 fatty acid in a concentration in the range from about 0.1 to about 3%, anda pharmaceutically acceptable vehicle.

26. The method according to claim 25, wherein the anti-parasitically active lipid is selected from the group consisting of glycerol monocaprate, glycerol monocaprylate, glycerol monolaurate, propylene glycol monocaprate, propylene glycol monocaprylate, propylene glycol monolaurate, glycerol dicaprin, glycerol dicaprylate, glycerol dilaurate, glycerol tricaprin, glycerol tricaprylate, glycerol trilaurate, octylglycerol, monomyristin, monopalmitolein, monoolein, propylene glycol monocaprylate, propylene glycol monolaurate, and any combination thereof.

27. The method according to claim 25 or 26, wherein said composition comprises said C8-C12 fatty acid, which is selected from capric acid, caprylic acid, lauric acid and any mixture thereof.